Haleon PLC Sponsored ADR (NYSE:HLN) Shares Sold by GAM Holding AG

GAM Holding AG cut its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 15.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 666,312 shares of the company's stock after selling 125,790 shares during the quarter. GAM Holding AG's holdings in Haleon were worth $6,856,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. FMR LLC lifted its position in Haleon by 3.7% during the fourth quarter. FMR LLC now owns 108,827,814 shares of the company's stock worth $1,038,217,000 after buying an additional 3,909,545 shares during the period. Wellington Management Group LLP lifted its position in Haleon by 67.5% during the fourth quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock worth $146,232,000 after buying an additional 6,175,835 shares during the period. Envestnet Asset Management Inc. lifted its position in Haleon by 0.8% during the fourth quarter. Envestnet Asset Management Inc. now owns 7,630,307 shares of the company's stock worth $72,793,000 after buying an additional 58,444 shares during the period. JPMorgan Chase & Co. lifted its position in Haleon by 18.3% during the fourth quarter. JPMorgan Chase & Co. now owns 6,014,903 shares of the company's stock worth $57,382,000 after buying an additional 930,701 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Haleon by 27.7% in the 4th quarter. Northern Trust Corp now owns 5,412,542 shares of the company's stock worth $51,636,000 after purchasing an additional 1,172,931 shares during the period. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Wall Street Zen upgraded Haleon from a "hold" rating to a "buy" rating in a report on Friday, June 6th. BNP Paribas upgraded Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. Barclays reiterated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Finally, HSBC reiterated a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Five analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Haleon presently has a consensus rating of "Moderate Buy" and an average target price of $12.33.

Haleon Stock Performance

Shares of HLN traded down $0.06 during mid-day trading on Friday, hitting $10.40. The stock had a trading volume of 14,895,917 shares, compared to its average volume of 9,121,184. The company has a market cap of $46.74 billion, a PE ratio of 26.65, a PEG ratio of 2.96 and a beta of 0.31. The company's fifty day simple moving average is $10.69 and its two-hundred day simple moving average is $10.11. The company has a quick ratio of 0.78, a current ratio of 0.98 and a debt-to-equity ratio of 0.53. Haleon PLC Sponsored ADR has a fifty-two week low of $8.25 and a fifty-two week high of $11.42.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.